Business Wire

SES and Intelsat Propose Joint Use of C-band by Satellite and Terrestrial Mobile Operators in the U.S.

Jaa

Leading satellite companies SES S.A. (Euronext Paris and Luxembourg Stock Exchange: SESG) and Intelsat S.A. (NYSE: I) today announced alignment on a proposal to the United States Federal Communications Commission (FCC) which seeks to protect the wide array of established satellite services in the 3700-4200 MHz C-band downlink spectrum while opening a specified portion of that spectrum for terrestrial mobile use.

The joint proposal, which was developed in response to the unique U.S. telecommunications environment, aims to protect the quality and reliability of the extensive services provided by satellite operators in C-band to U.S. broadcasters, media and data companies. The proposal ensures the continued seamless distribution of video and audio programming to more than 100 million U.S. households, and the reliable provision of critical data connectivity in rural areas and emergency situations, as well as services delivered to the U.S. government.

The proposal, which builds on an innovative model first put forward to the FCC by Intelsat and Intel Corporation in October 2017, sets a commercial and technical framework that would enable wireless operators to quickly access approximately 100 MHz of nationwide C-band downlink spectrum in the U.S., speeding the deployment of next generation 5G services.

The proposal specifies the creation of a consortium, which would be open to all C-band operators providing service to all or a portion of the lower 48 United States pursuant to FCC-issued licenses or grants of market access. The consortium would oversee the governance of the initiative, define and implement the methodology for spectrum clearance, and serve as the sole interface for market-based transactions with parties interested in deploying terrestrial mobile services in specific portions of the C-band. SES and Intelsat have begun briefing the FCC on this proposal.

Karim Michel Sabbagh, President and CEO of SES, said, “The C-band is and remains a critical component of the U.S. network architecture. Space and ground segment operators have invested billions of dollars in U.S. C-band networks and connectivity and generate important value out of it. It is therefore our duty and mission to protect the C-band in the U.S. from any form of disruption and preserve its use. The C-band satellite consortium is to be set up to ensure that the expansion of the C-band ecosystem in the U.S. will protect the interests of hundreds of established services and millions of American end-users, while at the same time paving the way for the creation of next generation 5G terrestrial services.”

Peter Pitsch, Associate General Counsel, Intel, said, “Intel's goal remains to facilitate timely access to high quality terrestrial 5G services. We welcome the announcement of the alignment of Intelsat and SES on significant details of the proposal, and plan to continue to support this market-based approach, which we believe paves the way for the accelerated deployment of 5G in the U.S.”

Intelsat CEO Stephen Spengler said, “Our priority continues to be creating a framework that provides certainty and protects the quality and reliability of the services we provide to our media, network services and government customers. Our proposed market-based solution provides a speedy resolution to the U.S. objective of accelerating deployment of 5G services. With Intelsat and SES now in agreement on major tenets of the framework and with the support of Intel, we are confident in our ability to implement this proposal quickly and efficiently, ultimately to the benefit of American consumers and the U.S. economy.”

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com

Follow us on:

Social Media
Blog
Media Library
White Papers

About Intelsat

Intelsat S.A. (NYSE: I) operates the world’s first Globalized Network, delivering high-quality, cost-effective video and broadband services anywhere in the world. Intelsat’s Globalized Network combines the world’s largest satellite backbone with terrestrial infrastructure, managed services and an open, interoperable architecture to enable customers to drive revenue and reach through a new generation of network services. Thousands of organizations serving billions of people worldwide rely on Intelsat to provide ubiquitous broadband connectivity, multi-format video broadcasting, secure satellite communications and seamless mobility services. The end result is an entirely new world, one that allows us to envision the impossible, connect without boundaries and transform the ways in which we live. For more information, visit www.intelsat.com.

Contact information

SES
Markus Payer, +352 710 725 500
Corporate Communications & PR
Markus.Payer@ses.com
or
Intelsat
Dianne VanBeber, +1 703-559-7406
Vice President, Investor Relations
dianne.vanbeber@intelsat.com
or
Intel
Lisa Malloy, +1 202-270-7600
Senior Director, Government Relations
lisa.malloy@intel.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54Tiedote

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Tradeshift Announces Q3 2018 Results19.10.2018 14:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00Tiedote

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Alibaba’s Robust Ecosystem Supercharges 2018 11.11 Global Shopping Festival19.10.2018 13:15Tiedote

Alibaba Group Holding Limited (NYSE:BABA) today officially kicked off the 2018 11.11 Global Shopping Festival in China’s capital, promising this year’s mega-event will be the largest-ever in terms of scale and reach. Businesses within the Alibaba ecosystem will jointly offer hundreds of millions of consumers an enriching experience that supports their pursuit of high-quality products, entertainment and fast, reliable services. The Festival will also demonstrate the enthusiasm of consumers and brands embracing Alibaba’s New Retail strategy – the convergence of online and offline retail through technology. “This year marks the 10th anniversary of 11.11. On the back of China’s explosive digital transformation, the Festival’s astounding growth over the past decade has powered the steady growth of quality consumption sought by Chinese shoppers. The evolution also showcases the development of the Alibaba ecosystem over time expanding well beyond e-commerce,” said Alibaba Group CEO Daniel Zha

Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC19.10.2018 13:08Tiedote

Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). The results showed that the sequential strategy was effective in delaying subsequent chemotherapy treatment and were published today in the journal Future Oncology. According to the study, the median time on treatment for sequential afatinib and osimertinib was 27.6 months. In this broad, real-world population, the clinical benefit was consistent across all patient subgroups, with particularly encouraging results seen in those with exon 19 deletion (Del19)-positive disease (median time on treatment 30.3 months) and Asian patients (median time on treatment 4

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme